Our Presence at SOT

Poster Presentations

Below is our preliminary list of posters to be presented by our attending scientists.

  • Cardiotoxicity

    Predicting Cardiac Risk of Anti-Cancer Drugs: A Role for Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
    Presented by: A. Bruening-Wright

    Abstract Number/Poster Board number: 3279/P248
    Session Title: Late-Breaking Poster Session 1
    Presentation Date and Time:  March 16th, 2017 8:30 11:45 AM
    Presentation Location: Hall A

    Combination Toxicity Study of Two Approved Cardiovascular Drugs
    Presenter: A. Chester, Gilead (Co-Authored by: C. Voyer, Charles River)

    Abstract Number/Poster Board number: 1699/P151
    Presenting Author: Anne Chester
    Session Title: Pharmaceutical Safety: Drug Development
    Presentation Date and Time:  March 14, 2017 9:30 AM to 12:45 PM

    Drugs in Development That Prolong QTc, Can We Identify the Good From the Bad?

    Presenter: B. Roche

    Abstract Number/Poster Board number: 1705/P157

    Session Title: Pharmaceutical Safety: Drug Development
    Presentation Date and Time:  March 14, 2017 9:30 AM to 12:45 PM

    Presentation Location: Hall A

  • Developmental and Reproductive Toxicology

    Are Satellite Rats needed for Toxicokinetic Assessment in Embryo-fetal Development Studies?

    Presented by: H. Emmen

    Abstract Number/Poster Board number: 3406/P378
    Session Title: Late-Breaking Poster Session 4
    Presentation Date and Time: March 16th, 2017 8:30 to 11:45 AM
    Presentation Location: Hall A

    Developmental and Reproductive Toxicity Evaluation of Dengvaxia®, the Sanofi Pasteur Tetravalent Dengue Vaccine

    Presented by: G. Ravel, Sanofi Pasteur (Co-Authored by: E. Lewis at Charles River)

    Abstract Number/Poster Board number: 1232/P356

    Session Title: Developmental and Juvenile Toxicity

    Presentation Date and Time: March 13th, 2017 9:30 AM to 12:45 PM

    Presentation Location: CC Exhibit Hall or Hall A

    Placental Transfer Investigation of a Monoclonal Antibody in the Pregnant Mouse Using Microsampling-coupled Bioanalysis

    Presented by: X. Manciaux

    Abstract Number/Poster Board number: 3415/P387

    Session Title: Late-Breaking Poster Session 4

    Presentation Date and Time: March 16th, 2017 8:30 to 11:45 AM

    Presentation Location: Hall A

  • General Toxicology

    Our exceptional team of scientists regularly designs and performs safety programs ranging from acute through chronic toxicity and carcinogenicity studies.

    Toxicology POSTER Presentations

    28-Day Somatic Gene Mutation Study of 1-Bromopropane in Female Big Blue® B6C3F1 Mice via Whole-Body Inhalation

    Presented by: M. Steljes, SLR International Corp (Co-Authored by:  J. Weinberg at Charles River)

    Abstract Number/Poster Board number: 2255/P613

    Session Title: Genetic Toxicity

    Presentation Date and Time: March 14th, 2017 1:15 to 4:30 PM

    Presentation Location: CC Exhibit Hall

    A Comparison of Selected Organ Weights and Clinical Pathology Parameters in Male and Female CD-1 and CByB6F1 Hybrid Mice 12-14 Weeks in Age
    Presented by: L. Dhiel

    Abstract Number/Poster Board number: 1719/P201
    Session Title: Pharmaceutical Safety: Drug Development
    Presentation Date and Time: March 14th, 2017 9:30 AM to 12:45 PM
    Presentation Location: CC Exhibit Hall or Hall A

    Comparison of the Long-Term Effects on Survival, Body Weight, and Food Consumption in Two Strains of Rats Used in Toxicology Studies Given Diets of 14% or 18% Protein Content
    Presented by: A. Viau

    Abstract Number/Poster Board number: 1718/P170
    Session Title: Pharmaceutical Safety: Drug Development
    Presentation Date and Time: March 14th, 2017 9:30 AM to 12:45 PM
    Presentation Location: CC Exhibit Hall or Hall A

    The Incidence of Rodents Rejected from Non Clinical Toxicology Studies due to Ophthalmology Findings
    Presented by: P. Mansell

    Abstract Number/Poster Board number: 1714/P166
    Session Title: Pharmaceutical Safety: Drug Development
    Presentation Date and Time: March 14th, 2017 9:30 AM to 12:45 PM
    Presentation Location: CC Exhibit Hall or Hall A

    Comparison of Early Morning Versus Overnight Pan Collection for Urine Assessment in Large Animals*
    Presented by: M. Guillot

    Abstract Number/Poster Board number: 1716/P168
    Session Title: Pharmaceutical Safety: Drug Development
    Presentation Date and Time: March 14th, 2017 9:30 AM to 12:45 PM
    Presentation Location: CC Exhibit Hall or Hall A

    Triple Cannulation Approach for Biodistribution Studies of Neurologically Active Compounds in the Large Animals*
    Presented by: J. Douville

    Abstract Number/Poster Board number: 1709/P161
    Session Title: Pharmaceutical Safety: Drug Development
    Presentation Date and Time: March 14th, 2017 9:30 AM to 12:45 PM
    Presentation Location: CC Exhibit Hall or Hall A

    Urine Collection for Group-Housed Mice in Toxicology Studies Using the LabSand® Techniques—An Alternative Method
    Presented by: A. Varela

    Abstract Number/Poster Board number: 1717/P169

    Session Title: Pharmaceutical Safety: Drug Development

    Presentation Date and Time: March 14th, 2017 9:30 AM to 12:45 PM

    Presentation Location: CC Exhibit Hall or Hall A

    Reversible Fur and Skin Pigmentation Changes in Large Animals and Long Evans Rats Following the Administration of AZD3293, a Novel β-Secretase Inhibitor*

    Presented by: P. Mansell (in collaboration with AstraZeneca)

    Abstract Number/Poster Board number: 3280/P249

    Session Title: Late-Breaking Poster Session 1

    Presentation Date and Time: March 16th, 2017 8:30 to 11:45 AM

    Presentation Location: Hall A

    Benefits and limitations of Positron Emission Tomography-Computed Tomography (PET-CT) and Magnetic Resonance Imaging (MRI)
    in Mice

    Presented by: N. Hébert (in collaboration with the Imaging Center of Sherbrooke (CIMS)

    Abstract Number/Poster Board number: 3345/P315

    Session Title: Late-Breaking Poster Session 2

    Presentation Date and Time: March 16th, 2017 8:30 to 11:45 AM

    Presentation Location: Hall A

    *Titles may have been modified due to their sensitive nature.

  • Immunotoxicology

    Our immunology groups provides fully integrated services to support toxicology and clinical studies that determine the safety of compounds, and define immunological endpoints and alterations of cellular function induced by test compounds.

    ImmunoToxicology POSTER Presentations

    Evaluation of T Cell-Dependent-Antibody Reponses in Large Animals Treated with an Immunossupressor or Immunostimulant, Using Two Antigens*
    Presented by: M. S. Piché

    Abstract Number/Poster Board number: 1986/P656
    Session Title: Immunotoxicology
    Presentation Date and Time: March 14th, 2017 9:30 AM to 12:45 PM
    Presentation Location: CC Exhibit Hall or Hall A

    *Titles may have been modified due to their sensitive nature.

  • Inflammation

    Cyclosporine A (CsA) Partially Prevents Progression of Colitis in an Acute DSS-induced Mouse Model
    Presented by: K. Norton

    Abstract Number/Poster Board Number: 2975/P527
    Session Title: Inflammation in Disease
    Presentation Date and Time: March 15th, 2017 1:15 PM to 4:30 PM
    Presentation Location: CC Exhibit Hall or Hall A

  • In Vitro Toxicology

    Our scientists have been leading the way in the development, validation and acceptance of various animal-free models. Many of our assays are direct replacements for tests or screenings done on animals.

    In Vitro Toxicology POSTER Presentations

    Development of a Phototoxicity Testing Strategy for Accurate Photosafety Evaluation of Pharmaceuticals Based on the Assessment of Possible Melanin Binding Effects
    Presented by: J. Rijk

    Abstract Number/Poster Board number: 1712/P164
    Session Title: Pharmaceutical Safety: Drug Development
    Presentation Date and Time: March 14th, 2017 9:30 AM to 12:45 PM
    Presentation Location: CC Exhibit Hall or Hall A

    Evaluation of the Effect of Occlusion on the Absorption of the Reference Test Item, [14C]‑Testosterone, Applied to Human Skin In Vitro

    Presented by: C.S. Roper

    Abstract Number/Poster Board number: 2197/P510
    Session Title: Skin
    Presentation Date and Time:  March 14th, 2017 1:15 PM to 4:30 PM
    Presentation Location: CC Exhibit Hall or Hall A

    Genotoxicity Assessment of Nanomaterials: Best Practices, Assays, and Methods

    Presented by: R. Elespuru, ILSI-HESI (Co-authored by: C. Farabaugh and L. Stankowski at Charles River)

    Abstract Number/Poster Board number: 2269/P627
    Session Title: Genetic Toxicology
    Presentation Date and Time:  March 14th, 2017 1:15 to 4:30 PM
    Presentation Location: CC Exhibit Hall or Hall A

    In Vitro Genotoxicity and Cytotoxicity of Electronic Nicotine Delivery Systems (ENDS) Aerosol Formers and Nicotine
    Presented by: M. Lee, Altria (co-authored by: M. Wells and S. Hurtado from Charles River)

    Abstract Number/Poster Board number: 2245/P603
    Session Title: Genetic Toxicity
    Presentation Date and Time: March 14th, 2017 1:15 PM to 4:30 PM
    Presentation Location: CC Exhibit Hall or Hall A

    Optimization of the Direct Peptide Reactivity Assay (DPRA) for Poorly Soluble Substances
    Presented by: J. Rijk (in collaboration with Shell)

    Abstract Number/Poster Board number: 2195/P508
    Session Title: Skin
    Presentation Date and Time: March 14th, 2017 1:15 PM to 4:30 PM
    Presentation Location: CC Exhibit Hall or Hall A

    Skin Sensitization Testing Strategy and In-House Fit-for-Purpose Validations at Charles River Laboratories
    Presented by: C.S. Roper

    Abstract Number/Poster Board number: 2737/P105
    Session Title: Alternatives to Mammalian Models I: Liver, Ocular, and Skin Alternatives
    Presentation Date and Time:  March 15th, 2017 1:15 PM to 4:30 PM
    Presentation Location: CC Exhibit Hall or Hall A

  • Laboratory Sciences Support

    Our Laboratory Sciences team balances scientific integrity, cost-effectiveness and regulatory compliance within the most stringent of time frames to deliver comprehensive support throughout the drug development process. We believe in remaining at the forefront of laboratory technology and have made significant investments in highly trained chemists, facilities and instrumentation to produce rapid and reliable data.

    Laboratory Sciences Support POSTER Presentations

    Humanized Monoclonal Antibody-Mediated Inhibition of NK Cell Detection by Flow Cytometry in Large Animals*
    Presented by: N. Makori

    Abstract Number/Poster Board number: 1987/P657
    Session Title: Immunotoxicology
    Presentation Date and Time:  March 14th, 2017 9:30 AM to 12:45 PM
    Presentation Location: CC Exhibit Hall or Hall A

    Validation of an Electrochemiluminescence (ECL) Method for the Quantitation of Calcitonin in Rat Serum
    Presented by: S. Cotton

    Abstract Number/Poster Board number: 2015/P121
    Session Title: Biomarkers
    Presentation Date and Time: March 14th, 2017 1:15 PM to 4:30 PM
    Presentation Location: CC Exhibit Hall or Hall A

    Development and Qualification of a Mass Spectrometric Immunoassay for Identification and Quantification of Wild-Type and Mutant Transthyretin in Human Serum

    Presented by: S. Fountain

    Abstract Number/Poster Board number: 3356/P327

    Session Title: Late-Breaking Poster Session 3

    Presentation Date and Time:  March 16th, 2017 8:30 to 11:45 AM

    Presentation Location:  Hall A

    Analytical Method Development for Polymeric Materials in Biological Fluids Using High Performance Liquid Chromatography Coupled with Tandem Mass Spectrometric Detection (HPLC-MS/MS)

    Presented by: E. Groeber

    Abstract Number/Poster Board number: 3275/P244

    Session Title: Late-Breaking Poster Session 1

    Presentation Date and Time: March 16th, 2017 8:30 to 11:45 AM

    Presentation Location: Hall A

    Development of an Automated High-Throughput LC/MS/MS method for the Analysis of a Neurotransmitter Panel in Mouse Striata
    Presented by: S. Cotton

    Abstract Number/Poster Board number: 3284/P253

    Session Title: Late-Breaking Poster Session 1

    Presentation Date and Time: March 16th, 2017 8:30 to 11:45 AM

    Presentation Location: Hall A

    *Titles may have been modified due to their sensitive nature.

  • Exhibitor Sessions

    These sessions will be recorded and made available for those unable to attend on The Source℠,
    our secure portal for technical, scientific and educational resources.

    All Exhibitor Sessions will be presented in Room 340 at the Baltimore Convention Center.
    Make sure to come by our booth (Booth 1825) to discuss further with our presenters after the session.

  • Beyond REACH

    MONDAY, MARCH 13

    13:30 PM – 14:30 PM

    SPEAKERS

    Daniel Newton, BS
    Senior Manager, Government Relations, SOCMA

    Jeannette Paulussen, MSc, PhD
    Head of Regulatory Affairs

    ABSTRACT

    Recent changes to REACH legislation and its guidance, the substance identity focus, etc., make it challenging to meet the 2018 deadline, and to register new substances. Companies should consider a global approach to testing of industrial chemicals, including regions such as China or USA with its updated TSCA requirements.

    OBJECTIVEs

    This presentation discusses the cost-effectiveness of taking a more global approach to REACH program designs by including endpoints and studies to fulfill a wider range of regulatory requirements. Recent changes to REACH will be reviewed alongside alterations to other guidelines, such as TSCA.

    BIO

    Mr. Newton’s main duties include analysis of and advocacy on legislative and regulatory affairs related to chemical risk management policies, primarily the Toxic Substances Control Act (TSCA).  He also manages PMNPro, SOCMA’s consulting service for companies complying with TSCA, specializing in the premanufacture notification (PMN) process for new chemicals entering the US marketplace. Before joining SOCMA, Mr. Newton served as an environmental analyst for an EPA contractor. Prior to that, he worked as an analytical chemist.

    Dr. Paulussen is the head of the Regulatory Affairs Department at the Charles River Den Bosch facility. She leads the 20+ person Regulatory Affairs team, which provides support for the registration of chemicals, biocides, agrochemicals and pharmaceutical products. After obtaining her PhD at the Faculty of Pharmacy at the University of Utrecht, she moved into regulatory affairs, providing legislative support with a background in human risk assessment for the agrochemical/chemical industry.

  • Quantitation of Biotherapeutics by LC/MS: Finding Its Groove in Preclinical Toxicology

    Tuesday, MARCH 14

    10:30 AM – 11:30 AM

    SPEAKERS

    Elizabeth Groeber, PhD
    Director, Bioanalytical Chemistry, Charles River

    Scott Fountain, PhD
    Executive Director, North American Laboratory Sciences, Charles River

    ABSTRACT

    LC/MS quantitation of biotherapeutics has evolved as a differentiated tool supporting investigative toxicology. Research demonstrates that this methodology 1.) satisfies FDA criteria for TK assessments; 2.) addresses limitations of ligand binding assays techniques related to selectivity of endogenous analogs and metabolites; and 3.) mitigates reagent generation issues.

    OBJECTIVEs

    The rationale and advantages to using LC/MS-based quantitation methodologies, compared to traditional large molecule quantitation approaches, will be explored. Case studies will be presented that illustrate complementary results obtained by using parallel LC/MS and standard assay methods. Considerations for LC/MS quantitation in preclinical toxicology will be discussed.

    BIOs

    Dr. Elizabeth Groeber is currently a director of bioanalytical chemistry at Charles River Laboratories. Her 20-year career spans contract research organizations and innovator pharma, including nine years with Pfizer in development and discovery roles.

     

    Dr. Scott Fountain is currently executive director of North American laboratory sciences and clinical support at Charles River Laboratories and chair-elect for the AAPS BIOTEC Section. Dr. Fountain received his PhD in analytical chemistry from the University of Michigan, and went on to work for Waters Corporation in a technical client-facing role following graduation. He interacted with his next employer, Pfizer, which was a client of Waters. During his career at Pfizer, he established a quantitative biomarker implementation group in Michigan and later a biotherapeutics and translational research group in California. He is the past chair of the Biomarkers in Translational Medicine Focus Group. Dr. Fountain has established and relied on a durable network of professional friendships to shape a professional career of over 20 years.

  • Quantitative Measures Associated with DNA and RNA Therapeutics

    WEDNESDAY, MARCH 15

    9:00 AM – 10:00 AM

    SPEAKERS

    Jonathan Reeves, PhD
    Scientific Director, Immunochemistry, Charles River

    ABSTRACT

    Increasing interest in the development of oligonucleotide therapeutics among biotech and large pharma companies has been recently fuelled by the approval of mipomersen. Sensitive and selective bioanalytical methodologies are key to the development process. Chromatographic and hybridization ELISA approaches will be reviewed, compared and contrasted.

    OBJECTIVEs

    An overview of oligonucleotide therapeutics in multiple clinical stages will be given. The available bioanalytical platforms for quantitation of oligonucleotide therapeutics will be discussed, with a focus on the hybridization ELISA assays.

    BIO

    Dr. Reeves has been with Charles River since 2006. He holds a PhD in cell biology from the University of Liverpool, and spent 6 years at the University of Glasgow and the Beatson Institute for Cancer Research gaining experience developing ELISA-based and immunohistochemical ligand binding assays. Following his postdoctoral work, he moved to Canada and worked for Procyon Biopharma in Montreal developing novel ELISA methodology for prostate cancer screening tests.

  • Trends, Trials and Triumphs in In Vitro Toxicology

    TUESDAY, MARCH 14

    3:00 PM – 4:00 PM

    SPEAKERS

    Warren Casey, PhD
    Director, U.S. National Toxicology Program's Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), National Institutes of Environmental Health Sciences (NIEHS)

    Leon Stankowski, PhD
    Scientific Director, Genetic and In Vitro Toxicology

    Jeroen Rijk, PhD
    Study Director, Discovery

    Clive Roper, BSc, PhD, CBiol, CSci, MRSB
    Head, In Vitro Sciences

    ABSTRACT

    In vitro alternatives for toxicology screening and animal testing are increasing in variety. While validation against animal tests is costly and may result in false rejection, human clinical and/or mechanistic data is revolutionizing our acceptance and understanding of these tests. Such knowledge will serve to guide our future testing strategies.

    OBJECTIVEs

    We will explore some of the complexities and successes met in the validation and acceptance of in vitro toxicology tests, highlighting how strides in adverse outcome pathways stand to benefit toxicology and drug development. In addition, we will discuss the advantages of in silico technologies in TK/PK studies.

    BIOs

    Dr. Warren Casey is director of the U.S. National Toxicology Program's Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), National Institutes of Environmental Health Sciences (NIEHS). He received his undergraduate degree in biochemistry and his PhD in microbiology from North Carolina State University, where he now serves as an adjunct associate professor in the Department of Microbiology. Prior to joining NICEATM, he was the manager of pharmaceutical microbiology at Glaxo, Inc.; head of biomarker development at GlaxoWellcome, Inc.; and a senior scientist for discovery and investigative toxicology at GlaxoSmithKline, Inc. He has authored and co-written more than 28 publications in peer-reviewed journals, presented at numerous scientific meetings, and holds three patents. Dr. Casey is a Diplomate of the American Board of Toxicology (DABT).

     

    Dr. Clive Roper is the head of in vitro sciences at Charles River’s Edinburgh facility. He is an expert in skin penetration, especially for safety testing of cosmetics and agrochemicals and for formulation selection for topical pharmaceuticals. He also has a strong personal interest in dermal metabolism. In his current role, he manages genetic toxicology, in vitro safety pharmacology (hERG), in vitro toxicology (e.g., skin and eye irritation and lung toxicology), skin penetration and bespoke and technology transfer testing. Dr. Roper has published many abstracts and posters and a number of peer-reviewed papers.

     

    Dr. Leon Stankowski is the scientific director of genetic and in vitro toxicology at Charles River in Skokie, IL. He is responsible for guiding research and development for new service offerings, and providing guidance on all aspects of toxicology to help clients reach their goal of regulatory approval for new products. He is responsible for evaluating and addressing adverse toxicology issues when they arise, as well as designing specialized protocols and mechanistic studies to resolve them. He regularly reviews study results and adverse outcomes for compounds being developed by various pharmaceutical and other companies. Dr. Stankowski has authored multiple publications.

     

    Dr. Jeroen Rijk finished his master study in food science at Wageningen University. His PhD thesis research, conducted at RIKILT - Institute of Food Safety in Wageningen, focused on hormone abuse in the veterinary sector. He was later appointed a postdoctoral researcher at RIKILT, and worked for four years in the field of endocrine disruption. Dr. Rijk came to Charles River’s Den Bosch facility in 2013, where his current work in the fields of in vitro ADME and in vitro toxicology focuses on endocrine disruption, skin sensitization and ADME.

  • Continuing Education Course

    Members of Charles River's scientific staff are participating in the following CE course during
    this year's SOT Annual Meeting.

  • Sunrise Mini-Course (SR01) │ Molecular Imaging for Toxicologists

    SUNDAY, MARCH 12

    7:00 AM – 7:45 AM

    LOCATION

    Baltimore Convention Center

    Chairperson

    Aurore Varela
    Charles River Laboratories, Senneville, QC

    OVERVIEW

    Advanced in vivo imaging techniques such as magnetic resonance and nuclear and tomographic imaging are the gold standard in several areas of clinical medicine for diagnosis and guided therapy, and play an increasing role in clinical trials, being an integral part of the drug development process. Imaging sciences have known an incredible development during the last decades, and many techniques, such as MRI, PET, SPECT, and X-ray-computed tomography, have become indispensable.

    The applications of in vivo translational imaging are now extending further into drug discovery and development, and have the potential to considerably accelerate the process, reduce the cost, significantly affect the drug development process, and comply with the 3Rs. It is important to understand the technologies and their applications and limitations. Imaging technology includes a range of modalities such as magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), computed tomography (CT), in vivo optical imaging, and ultrasound. These noninvasive and quantitative techniques provide not only anatomical evaluation but also functional and molecular information that can access the mechanisms of drug action or its toxicity.

    The future trends will certainly be in multimodality imaging, combining high sensitivity and molecular techniques with high spatial resolution and morphological techniques. Imaging stands out as one of the most promising translational techniques for making early-phase go/no-go decisions by helping to identify compounds that are likely to fail in later phases, so that only the most promising candidates are moved forward. Imaging technologies can improve the drug development process, not only through the development of safer and more effective drugs, but also by reducing timelines. Better prediction of toxicology in an earlier stage will certainly limit the large contribution of drug failure due to adverse effect in later-stage development.

    Although imaging has not yet found a major place in safety pharmacology and toxicology studies, several applications exist in cardiovascular, neurology, teratology, and reproductive toxicity. The same technologies and physiological and pathological parameters can be quantified for both pharmacology and toxicology applications, confirming the role of in vivo imaging as a translational biomarker for both efficacy and safety assessment.

    This overview provides the opportunity to review fundamentals of molecular imaging and important applications of imaging in different therapeutic areas, discover opportunities for decision-making in the preclinical phase, examine the challenges of GLP validation, and actually integrate imaging approaches into safety assessment in drug development.

     

    The Wonderful World of Molecular Imaging: Understand the Technology. Roger Lecomte, Université de Sherbrooke, Sherbrooke, QC

    Imaging Biomarkers for Decision Making in Drug Discovery. Paul J. McCracken, Eisai AiM Institute, Andover, MA

  • Workshops

    Roundtable Session

  • Managing COI and Bias in a CRO Setting

    MONDAY, MARCH 13

    12:30 PM – 1:50 PM

    LOCATION

    Baltimore Convention Center

    PRESENTER

    Pragati Sawhney Coder

    Charles River Laboratories, Ashland, OH

    Bias and Conflict of Interest in Conducting Research and Risk Assessments: Perspectives from Academia, Government, Industry, and Others

    Roundtable Session OVERVIEW

    Charges or claims of conflict of interest (COI) are made with increasing frequency with regard to suspicion that personal employment, associations, or funding sources will interfere with the ability of a scientist to objectively conduct or interpret studies, and/or serve on peer review or advisory panels. A frequent concern is funding sources. As public funding for scientific research decreases and becomes more competitive, researchers are seeking funding from other sources (e.g., nonprofit organizations, special interest groups, industry, foundations, and advocacy groups. It is important to recognize possible sources of COI and bias and develop ways to mitigate the potential effects.

     

    This session will provide an opportunity for participants to openly discuss issues regarding conflict of interest, and how COI and bias might affect scientists’ work, as well as their integrity and credibility. It will begin with a philosopher of science examining three philosophical criteria for objectivity in science: transparency, reproducibility, and critical review. This will be followed by scientists from various sectors (government, contract research organization [CRO], academia, private sector, and scientific society) who will reflect upon COI and potential for bias in their professional work (e.g., interpretation and application of their work), and how one might avoid or manage biases and conflicts of interest.

  • Squeezing more out of iPSC-derived Cardiomyocytes:
    Providing better solutions through increased functionality and integrative analyses

    Wednesday, MARCH 15

    12:00 PM – 1:00 PM

    LOCATION

    Room 337

    PRESENTER

    Presented by: ACEA Biosciences with Andrew Bruening-Wright from Charles River

    Roundtable Session OVERVIEW

    This forum showcases practical advances in xCELLigence CardioECR and iPSC-cardiomyocyte-based solutions for toxicity studies.  Specifically, data will be presented illustrating increased cardiomyocyte functionality and how integrating electrical and mechanical responses provides mechanistic and translatable results from a variety of chemical classes including small molecule kinase inhibitors and inotropic compounds.

  • SPECIALTY SPONSORSHIPS

    Charles River would like to thank the Society, as well as all of those who serve on special-interest groups.
    We all benefit from your contributions, and we are proud to sponsor many for these groups.

  • Charles River 2017 Society of Toxicology Annual Meeting and ToxExpo Sponsorships

     

    •  Diamond Sponsor: Society of Toxicology
    •  SOT 2017 Specialty Session (SS) Sponsorships
    •  Reproductive and Developmental Toxicology
    •  Toxicology and Exploratory Pathology
    •  Ocular Toxicology
    •  Dermal Toxicology Specialty Section
    •  SOT 2017 Special Interest Group (SIG) Sponsorships
    • Amercian Association of Chinese in Toxicology (AACT)
    • Hispanic Organization of Toxicologists (HOT)
    •  Women in Toxicology
    •  SOT 2017 Contemporary Concepts in Toxicology (CCT)
    • Metabolic Syndrome Bench to Clinic

© 2016 Charles River Laboratories International, Inc.